Detalhe da pesquisa
1.
Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.
Int J Cancer
; 149(5): 1166-1180, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33890294
2.
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Int J Cancer
; 147(8): 2293-2302, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468570
3.
Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma.
Br J Cancer
; 122(6): 835-846, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31937923
4.
Reactive oxygen species in cancer stem cells of head and neck squamous cancer.
Semin Cancer Biol
; 53: 248-257, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29935313
5.
A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.
Int J Cancer
; 142(1): 156-164, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28906000
6.
pN status predicts outcomes in surgically treated pT1-pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study.
Eur Arch Otorhinolaryngol
; 275(11): 2787-2795, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30159726
7.
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Int J Cancer
; 141(6): 1215-1221, 2017 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28560858
8.
A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Int J Cancer
; 136(12): 2940-8, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25404014
9.
The impact of time between surgery and adjuvant chemoradiotherapy in advanced oral cavity squamous cell carcinoma.
Front Oncol
; 14: 1393910, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38774413
10.
Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.
Oral Oncol
; 149: 106678, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38219707
11.
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
Front Oncol
; 14: 1283266, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38384801
12.
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.
Eur J Cancer
; 203: 114038, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38579517
13.
Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Front Oncol
; 13: 1107134, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37427101
14.
Animal models for personalized treatment options.
Int J Clin Pharmacol Ther
; 55(8): 698-700, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28696202
15.
Developmental delay in hypoxia-induced HO-1 expression predisposes to gut injury.
J Perinat Med
; 40(2): 191-7, 2012 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22718607
16.
Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.
Front Oncol
; 12: 730785, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35155222
17.
Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers.
Cancers (Basel)
; 14(11)2022 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681790
18.
Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients.
Cancers (Basel)
; 14(2)2022 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35053585
19.
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Oncol Res Treat
; 45(6): 319-325, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34915492
20.
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study.
Eur J Cancer
; 169: 146-155, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35569281